Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by Wall Street Zen

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

OMCL has been the topic of several other reports. Wells Fargo & Company raised their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Piper Sandler reissued an “overweight” rating and set a $49.00 price objective (down previously from $63.00) on shares of Omnicell in a report on Friday. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a report on Wednesday. Benchmark upped their target price on Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.29.

Omnicell Trading Down 5.1%

NASDAQ:OMCL opened at $37.07 on Friday. The company has a market capitalization of $1.66 billion, a P/E ratio of 926.98, a P/E/G ratio of 2.97 and a beta of 0.78. The stock’s 50 day moving average price is $46.22 and its 200 day moving average price is $36.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.43. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same period in the prior year, the firm earned $0.60 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, research analysts forecast that Omnicell will post 1.09 EPS for the current fiscal year.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 2.52% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in shares of Omnicell in the 2nd quarter valued at about $26,000. First Horizon Corp acquired a new position in Omnicell in the third quarter valued at approximately $31,000. Farther Finance Advisors LLC boosted its stake in Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after acquiring an additional 1,036 shares during the last quarter. LSV Asset Management bought a new position in Omnicell in the third quarter valued at approximately $97,000. Finally, Tower Research Capital LLC TRC grew its holdings in Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after acquiring an additional 3,932 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Company raised FY‑2026 and Q1 guidance above Street estimates (FY EPS 1.65–1.85 vs. consensus ~1.53; Q1 EPS 0.26–0.36 vs. ~0.22) and set revenue target roughly $1.215B–$1.255B, signaling confidence in recovery and product-led growth. BusinessWire: FY & Q4 results
• Positive Sentiment: Analyst upgrade: Bank of America raised Omnicell to Buy, citing a new product cycle (Titan XT, OmniSphere) that could drive revenue revisions and multi‑year growth upside. Investing.com: BofA upgrade
• Neutral Sentiment: Management emphasized strong demand for new platforms (Titan XT, OmniSphere) on the earnings call and provided a slide deck; revenue was roughly in line with expectations (+2.3% YoY). Seeking Alpha: Earnings call transcript
• Negative Sentiment: Q4 EPS missed estimates ($0.40 vs. $0.47 consensus) and declined from $0.60 a year ago, highlighting near‑term margin pressures; investors punished the print despite revenue guidance upside. Zacks: EPS miss
• Negative Sentiment: Some sell‑side caution remains: BTIG reiterated a Hold, pointing to near‑term profitability headwinds and a premium valuation that could limit upside until margins improve. TipRanks: BTIG Hold
• Negative Sentiment: High intraday volume and headlines noting a share plunge reflect short‑term selling pressure as traders react to the EPS miss and margin commentary despite guidance. Yahoo Finance: Why shares plunging

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.